Key Findings
Lonza, a global leader in contract development and manufacturing (CDMO) services, has unveiled plans to construct a significant new commercial spray-drying facility in Bend, Oregon, USA. This strategic expansion is designed to cement Lonza’s position as a leading CDMO provider for commercial-scale spray-dried dispersion (SDD) PSD-4 technology within the US market. The facility, projected to be operational by 2029, will generate over 80 new jobs and substantially enhance manufacturing capabilities for complex pharmaceutical formulations, thereby robustly supporting pharmaceutical companies in bringing new drugs to market.
Technical/Clinical Details
Spray-dried dispersion (SDD) is a widely utilized technology for enhancing the solubility and bioavailability of poorly soluble drug compounds. Lonza’s planned PSD-4 technology specifically enables high-efficiency and high-quality commercial-scale manufacturing of SDD formulations. The process involves dissolving the active pharmaceutical ingredient (API) and a polymer in a solvent, then atomizing this solution into fine droplets within a stream of hot gas. Rapid solvent evaporation results in the formation of a homogeneous amorphous solid dispersion. The new facility will be equipped with state-of-the-art spray dryers and ancillary equipment, capable of handling a diverse range of APIs and adhering to stringent GMP standards. This will maximize the efficacy of oral formulations and provide flexible solutions to meet demands from late-stage clinical development through commercial production.
Background & Context
In contemporary drug development, approximately 70% of new drug candidates face challenges with aqueous solubility. Effective formulation technologies for these poorly soluble drugs are therefore indispensable for ensuring patient access and maximizing therapeutic outcomes. Lonza’s heightened investment in SDD technology, as a major CDMO, underscores the pharmaceutical industry’s collective effort to address this critical challenge. The expansion of manufacturing presence in the US offers strategic advantages, including strengthening supply chains, reducing lead times, and facilitating rapid response to local clients. This is particularly crucial for accelerating the development of complex small molecule drugs and biologics.
Strategic Significance & Outlook
The completion of the new spray-drying facility in Bend, Oregon, is expected to further enhance Lonza’s competitive edge as a CDMO, making it an even more attractive partner for clients requiring highly potent compounds and specialized formulations. This facility embodies Lonza’s commitment to ‘science-based decision-making’ and a ‘customer-centric approach,’ forming a core component of its long-term growth strategy. By offering comprehensive services from early-stage drug development through commercialization, Lonza is poised to further drive innovation and patient contributions within the global pharmaceutical industry. In the future, the facility has the potential to serve as a next-generation pharmaceutical manufacturing platform through the integration of a broader array of formulation technologies and AI-powered process optimization.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments